key: cord-0961129-xkuey7ly authors: Raval, Nilesh; Djougarian, Anna; Lin, James title: Central retinal vein occlusion in the setting of COVID-19 infection date: 2021-04-02 journal: J Ophthalmic Inflamm Infect DOI: 10.1186/s12348-021-00241-7 sha: 017105fa4d6510cf75908681a286c7059b1421f0 doc_id: 961129 cord_uid: xkuey7ly nan angiotensin converting enzyme, rheumatoid factor, homocysteine, C-reactive protein, erythrocyte sedimentation rate, and thrombophilia panel, were unremarkable. The patient was treated with intravitreal antivascular endothelial growth factor (anti-VEGF) injections of bevacizumab. After a series of injections, the macular edema decreased significantly and the patient's visual acuity improved to 20/30 OD (Fig. 2b ). COVID-19-associated coagulopathy has been documented and studied since the onset of the pandemic [1] . Autopsy findings of patients with severe COVID-19 infection have demonstrated a hallmark diffuse small vessel thrombosis thought to be caused by complement-mediated microvascular injury, with platelet-fibrin microthrombi regularly found in venules, arterioles, and capillaries [2] . In addition, affinity of SARS-CoV-2 for vascular endothelial cell angiotensin-converting enzyme-2 (ACE2) receptors has been shown to activate apoptotic pathway signaling and prothrombotic cascades [3] . Hypercoagulability is a major risk factor for CRVO, and it is imperative to rule out other causes of CRVO in an otherwise healthy patient. Our patient did not have any significant medical history and infectious, inflammatory, and hypercoagulable studies were negative. There have only been a small number of cases of COVID-19associated CRVO in recent literature [4] [5] [6] . Our patient's positive RT-PCR SARS-CoV-2 assay and subsequent visual symptoms support the possibility that the pro-thrombotic state created by COVID-19 contributed to the development of CRVO. This case builds upon the existing literature that demonstrates the occurrence of CRVO in the setting of COVID-19. Patients with COVID-19 are at risk for vascular occlusive events, and early detection and treatment are paramount in restoring visual function. COVID-19 and its implications for thrombosis and anticoagulation Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Endothelial cell infection and endotheliitis in COVID-19 Retinal vein occlusion in COVID-19: a novel entity Impending central retinal vein occlusion in a patient with coronavirus disease 2019 (COVID-19) Central retinal vein occlusion in a young healthy COVID-19 patient: a case report Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Not applicable. Authors' contributions AD and JL worked together to diagnose the patient, and JL provided treatment for the patient with regular follow-up. NR compiled the images and was primary author of the case report. All authors read and approved the final manuscript. This research is supported by gifts from Lewis Henkind, as well as the Irving and Branna Sisenwein Endowment Fund to the Department of Ophthalmology, Montefiore Medical Center.Availability of data and materials Not applicable. Ethics approval and consent to participate Not applicable. Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal. The authors declare that they have no competing interests.